Chantibody Therapeutics Inc. is a biotech company based in Menlo Park, California that focuses on the discovery and development of transformational therapeutics to combat life-threatening diseases, especially cancer. We've developed a proprietary in silico empowered antibody discovery platform as a solid foundation for innovative biologics with diverse formats (mAb, bispecific, multi-specific antibody and fusion protein), and other diverse modalities such as CAR-T, mRNA, and antibody conjugates within our integrated ecosystem. The Chantibody team encompasses industry veterans with proven track records of bringing novel biologics to global clinical trials.